沐舒坦联合普米克令舒、可比特雾化吸入治疗AECOPD疗效观察

目的探讨沐舒坦联合普米克令舒(布地奈德)、可比特(复方异丙托溴铵)雾化吸入治疗慢性阻塞性肺病急性加重期(AECOPD)的临床疗效。方法 80例患者随机分为治疗组和对照组各40例。治疗组在常规治疗的基础上加沐舒坦30mg联合普米克令舒1mg、可比特2.5ml,生理盐水5 ml稀释后氧气驱动雾化吸入,1日2次,对照组在常规的基础上加普米克令舒1mg、可比特2.5ml,生理盐水5 ml稀释后氧气驱动雾化吸入,每日2次,两组治疗后对临床症状,体征改善时间,实验室检查,肺功能及动脉血气进行比较。结果治疗前两组各项观察指标无差异,(P0.05),治疗后治疗组在临床症状、体征改善时间,实验室检查,肺功能及动脉血气结果与对照组比较有显著好转,差异有统计学意义(P0.05)。结论沐舒坦联合普米克令舒、可比特雾化吸入治疗(AECOPD)有显著疗效,且方便、简单、安全、值得推广使用。

Mucosolvan joint pulmicort,combivent inhalation treatment of AECOPD

Objective To discuss the clinical efficacy of Mucosolvan joint pulmicort （budesonide）, combivent （compound ipratropium romide） inhalation treatment of acute exacerbation of chronic obstructive pulmonary disease （ AECO- PD）. Methods 80 cases of AECOPD were randomly divided into treatment group and control group, 40 cases for each group. In addition to conventional treatment, oxygen atomization inhalation was given to treatment group, which contained Mucosolvan 30 mg combined with pulmicort Img and combivent 2.5 ml diluted in saline 5 ml, twice a day; while in control group oxygen atomization inhalation was given which contained Mueosolvan I mg and combivent 2.5 ml diluted in saline 5 ml twice a day. Both groups were compared for the time to improvement of clinical symptoms and signs, laboratory tests, pulmonary function and arterial blood gas. Results There was no significant difference in indicators between the two groups before treatment （ P 〉 0.05 ）. After treatment, treatment group was superior to control group in the time to improvement of clinical symptoms and signs, laboratory tests, pulmonary function and arterial blood gas results, and the difference was statlsticaUy significant （P 〈 0.05）. Conclusions Mucosolvan joint pulmieort, combivent inhalation treatment of AECOPD has significant curative effects, and is convenient, simple, safe and worthy of promotion.